Please ensure Javascript is enabled for purposes of website accessibility

The 3 Most Resilient Stocks in the Bear Market Today

By Keith Speights - Mar 28, 2020 at 12:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks have soared while the overall market tanked. But are they buys?

If you threw a dart at a dartboard covered with every stock ticker on the market, the odds are overwhelmingly in favor of you hitting a stock that's down so far in 2020. Only a few have managed to rise in the midst of the massive meltdown caused by the novel coronavirus pandemic. Even fewer have delivered impressive year-to-date gains.

But a handful of stocks have managed to swim against the tide in a spectacular way, more than tripling in less than three months. Here are the three most resilient stocks in the bear market today.

Four arrows pointing down with one brightly lit arrow pointing up

Image source: Getty Images.

1. Co-Diagnostics

Shares of Co-Diagnostics (CODX -6.08%) have skyrocketed more than 920% so far this year. The stock first really captured investors' attention in January when the company announced that it had completed the core design for a novel coronavirus diagnostic test. 

As the COVID-19 outbreak spread beyond China into other countries, Co-Diagnostics rapidly became one of the hottest stocks on the market. Its shares received a huge boost in late February when Co-Diagnostics announced FDA clearance for its novel coronavirus diagnostic test.

At one point in early March, Co-Diagnostics stock was up nearly 1,900% year to date. Although shares didn't remain at that lofty level very long, Co-Diagnostics remains one of the biggest winners in the current bear market, with the company launching its coronavirus diagnostic test quickly thanks to the FDA easing regulatory requirements. 

2. Trillium Therapeutics

Trillium Therapeutics' (TRIL) shares are up close to 290% year to date. And the meteoric rise for the biotech stock has nothing to do with the coronavirus at all. Instead, Trillium benefited from Gilead Sciences' (GILD -0.47%) announcement on March 2 that it plans to acquire Forty Seven (FTSV) for $4.9 billion.

Although Trillium hasn't been named as a potential acquisition target itself, Gilead's buyout of Forty Seven makes Trillium much more intriguing to investors. Both Trillium and Forty Seven are developing drugs that block CD47, which is a protein that signals to the body's immune cells to avoid destroying cancer cells. 

The CD47 programs of Forty Seven and Trillium aren't too far apart in terms of development progress. With Gilead valuing Forty Seven so highly, it's not surprising that Trillium has been a huge winner. Even after its big gains, the company's market cap is still only around $300 million.

3. Novavax

Novavax (NVAX -8.19%) ranks as another very resilient biotech stock as the market has dropped. Its shares have more than tripled due to a couple of big developments.

First, Novavax has emerged as a favorite for investors because of its coronavirus vaccine program. The company announced on Feb. 26 that it expected to begin clinical testing of its experimental vaccine for protecting against novel coronavirus disease COVID-19 by late spring. Novavax's previous experience developing vaccines for MERS and SARS, which are also members of the coronavirus family, gave it a solid foundation from which to start.

Second, the biotech announced positive results on March 24 from a late-stage clinical study evaluating influenza vaccine NanoFlu. Novavax said that NanoFlu demonstrated non-inferiority compared to leading flu vaccine FluZone Quadrivalent in immunizing against four strains of influenza. The company now plans to move forward with filing for regulatory approval of its flu vaccine. 

Are they buys?

I'm skittish about investing in two of these high-flying stocks. But I like one of them.

Co-Diagnostics faces plenty of competition in the coronavirus testing market. Demand is so great right now that all of these companies should be successful. However, that dynamic won't last forever. 

Although I think Trillium's CD47 program is promising, the biotech is still only in early stage testing. There's a long way to go. There's also no guarantee that Trillium will be bought out like Forty Seven.

That leaves Novavax. I've been a fan of Novavax for quite a while. Based on its positive phase 3 results for NanoFlu, I expect the company will ultimately win FDA approval for the flu vaccine and that it will be a commercial success. My view is that Novavax is a great acquisition target for bigger drugmakers. Even if it isn't acquired, I think the stock still has room to run.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$39.37 (-8.19%) $-3.51
Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$3.86 (-6.08%) $0.25
Trillium Therapeutics Inc. Stock Quote
Trillium Therapeutics Inc.
TRIL
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.02 (-0.47%) $0.31
Forty Seven, Inc. Stock Quote
Forty Seven, Inc.
FTSV

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.